E. S. Newlands

Publication List Details

Period

1995 - 2008

Number

55

Co-Authors

Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE) (2008)

Wang, J., Short, D., Sebire, N. J., Lindsay, I., Newlands, E. S., Schmid, P., ...

Objectives: To evaluate the efficacy and toxicity of paclitaxel and cisplatin alternating with paclitaxel and etoposide doublet regimen (TP/TE), for salvage of patients with high-risk gestational...

Outcome of twin pregnancies with complete hydatidiform mole and healthy co-twin (2002)

Sebire, N.J., Foskett, M., Paradinas, F.J., Fisher, R.A., Francis, R.J., Short, D., ...

We assessed 77 twin pregnancies, comprising complete hydatidiform mole (CHM) and healthy co-twin, to ascertain the risks to the mother and baby of continuing the pregnancy, versus termination. 24...

Repetitive complete hydatidiform mole can be biparental in origin and either male or female (2000)

Fisher, R.A., Khatoon, R., Paradinas, F.J., Roberts, A.P., Newlands, E.S.

Complete hydatidiform mole (CHM) is an abnormality in pregnancy due to a diploid conception which is generally androgenetic in origin, i.e. all 46 chromosomes are paternally derived. We have examined...

Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy (1997)

Bower, M., Newlands, E. S., Holden, L., Rustin, G. J. S., Begent, R. H. J.

Background: An alternating combination chemotherapy schedule for advanced nonseminomatous germ cell tumours (NSGCT) has been in use since 1977. Patients and Methods: Three hundred thirty-nine men...

Secondary tumours following etoposide containing therapy for germ cell cancer (1995)

Boshoff, C., Begent, R. H. J., Oliver, R. T. D., Rustin, G. J., Newlands, E. S., Andrews, R., ...

Background Reports have implied etoposide as the cause of secondary leukaemia in patients treated for germ cell cancer. Patients and methods Between 1979 and 1992, 679 male patients with germ cell...

Two methods for detecting different aspects of the immune response to a xenograft in mice

Newlands, E. S.

Two radiolabel assays of immunity to a xenograft in mice are described. One detects definite cell death while the other, which is more sensitive, detects both cell death and the inhibition of DNA...

Computer system for assisting with clinical interpretation of tumour marker data.

Leaning, M. S., Gallivan, S., Newlands, E. S., Dent, J., Brampton, M., Smith, D. B., ...

OBJECTIVE--To design and evaluate a computer advisory system for the treatment of gestational trophoblastic tumour. DESIGN--A comparison of clinicians' treatment decisions with those of the computer...

Selective blocking of T cell-mediated in vitro cytotoxicity to a xenogeneic tumour by anti-immunoglobulin sera.

Newlands, E S, Hay, F C, Roitt, I M

Rejection of a xenograft by BALB/c mice results in a highly potent immune peritoneal population. When these immune cells are analysed by using two in vitro assays in parallel, at least two active...

Effective treatment for malignant mediastinal teratoma.

Parker, D, Holford, C P, Begent, R H, Newlands, E S, Rustin, G J, Makey, A R, ...

Primary malignant mediastinal teratoma is a rare tumour previously regarded as inevitably fatal. In a series of eight male patients with a mean age of 24 years five remain alive and well. All...

Long term survival after treatment of disseminated T cell lymphoma presenting with tracheal obstruction in a patient with coeliac disease.

Seddon, D J, Chung, K F, Paradinas, F J, Newlands, E S, Snashall, P D

A 46 year old man with coeliac disease and upper airway obstruction was thought to have undifferentiated carcinoma of the trachea. Subsequent immunohistological examination showed that the neoplasm...

Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells.

Baer, J. C., Freeman, A. A., Newlands, E. S., Watson, A. J., Rafferty, J. A., Margison, G. P.

Temozolomide (8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4-(3H)-one) has shown promising activity in Phase I trials against some brain (glioma) and skin (melanoma, mycosis fungoides)...

Response of differentiated but not anaplastic teratoma to interferon.

Rustin, G. J., Kaye, S. B., Williams, C. J., Newlands, E. S., Bagshawe, K. D., Toy, J. L.

A Phase 2 trial was conducted using intramuscular lymphoblastoid interferon (IFN, Wellcome Research Laboratories), 4 MU per day, in 10 patients with chemotherapy-resistant teratomas. There was...

Genetic evidence that placental site trophoblastic tumours can originate from a hydatidiform mole or a normal conceptus.

Fisher, R. A., Paradinas, F. J., Newlands, E. S., Boxer, G. M.

The genetic origin of two placental site trophoblastic tumours was established using a Y chromosome-specific and locus-specific minisatellite probes. A gestational origin was confirmed for both...

Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856).

Newlands, E. S., Blackledge, G. R., Slack, J. A., Rustin, G. J., Smith, D. B., Stuart, N. S., ...

Temozolomide (CCRG 81045: M&B 39831: NSC 362856) is an analogue of mitozolomide displaying similar broad spectrum activity in mouse tumours, but showing considerably less myelosuppression in the...

Doppler assessment of the uterine circulation and the clinical behaviour of gestational trophoblastic tumours requiring chemotherapy.

Long, M. G., Boultbee, J. E., Langley, R., Newlands, E. S., Begent, R. H., Bagshawe, K. D.

The haemodynamics of the uterine arteries and myometrium were assessed using Doppler ultrasound in forty consecutive patients requiring treatment for invasive mole and choriocarcinoma. The...

Plasma and tissue disposition of mitozolomide in mice.

Brindley, C. J., Antoniw, P., Newlands, E. S.

When mitozolomide was administered i.p. to mice, drug disposition appeared to fit a simple, one-compartment kinetic model with an elimination half-life of less than 1 h. The disposition of...

Tissue distribution and tumour localization of 99m-technetium-labelled liposomes in cancer patients.

Richardson, V. J., Ryman, B. E., Jewkes, R. F., Jeyasingh, K., Tattersall, M. N., Newlands, E. S., ...

The possible use of liposomes (phospholipid vesicles) to direct cytotoxic drugs to tumours has led us to investigate the tissue localization of i.v. injected 99m-Tc-labelled liposomes in cancer...

Chemotherapy of advanced malignant teratomas.

Newlands, E. S., Begent, R. H., Kaye, S. B., Rustin, G. J., Bagshawe, K. D.

Between 1977 and November 1979 we have treated 53 patients with malignant teratomas (43 males, 10 females). Thirty (70%) out of the 43 male patients had advanced and bulky disease at the time of...

Problems of interpretation of serum concentrations of alpha-foetoprotein (AFP) in patients receiving cytotoxic chemotherapy for malignant germ cell tumours.

Coppack, S., Newlands, E. S., Dent, J., Mitchell, H., Goka, G., Bagshawe, K. D.

Serial determinations of serum alpha-foetoprotein (AFP) concentrations are well established in monitoring the response to therapy of malignant germ cell tumours. Using a radioimmunoassay (RIA) with a...

Clinical trial of combination chemotherapy and specific active immunotherapy in disseminated melanoma.

Newlands, E. S., Oon, C. J., Roberts, J. T., Elliott, P., Mould, R. F., Topham, C., ...

Fifty-six patients with disseminated malignant melanoma were randomly allocated to two treatment groups. The first group C received combination chemotherapy consisting of DTIC and ICRF 159. The...

Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma.

Woll, P. J., Crowther, D., Johnson, P. W., Soukop, M., Harper, P. G., Harris, M., ...

Temozolomide, an imidazotetrazine derivative, was given to 18 patients with low-grade non-Hodgkin's lymphoma (NHL) at a dose of 750 mg m-2 orally, divided over five consecutive days, escalated to...

O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma.

Middleton, M. R., Lunn, J. M., Morris, C., Rustin, G., Wedge, S. R., Brampton, M. H., ...

Resistance of tumour cells to methylating and monochloroethylating agents in vitro and in vivo has been linked to levels of the DNA repair protein O6-methylguanine-DNA methyltransferase (MGMT). In a...

High-dose etoposide with granulocyte colony-stimulating factor for mobilization of peripheral blood progenitor cells: efficacy and toxicity at three dose levels.

Kanfer, E. J., McGuigan, D., Samson, D., Abboudi, Z., Abrahamson, G., Apperley, J. F., ...

High-dose etoposide (2.0-2.4 g m(-2)) with granulocyte colony-stimulating factor (G-CSF) is an effective strategy to mobilize peripheral blood progenitor cells (PBPCs), although in some patients this...

O6-benzylguanine enhances the sensitivity of a glioma xenograft with low O6-alkylguanine-DNA alkyltransferase activity to temozolomide and BCNU.

Wedge, S. R., Newlands, E. S.

The effect of the O6-alkylguanine-DNA alkyltransferase (AGT) inhibitor, O6-benzylguanine (O6-BG), on the anti-tumour activity of 8-carbamoyl-3-methylimidazo [5,1-d]-1,2,3,5-tetrazine-4(3H)-one...

Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro.

Wedge, S. R., Porteus, J. K., May, B. L., Newlands, E. S.

Depletion of the DNA repair protein O(6)-alkylguanine-DNA alkyltransferase (AGT) with O(6)-benzylguanine (O(6)-BG) has been widely shown to enhance 1,3-bis(2-chloroethyl)-nitrosourea (BCNU) activity....

Phase I trial of elactocin.

Newlands, E. S., Rustin, G. J., Brampton, M. H.

Elactocin is a novel anti-tumour antibiotic which has potent activity in vitro against a range of tumours. This phase I trial of elactocin identified the dose-limiting toxicity as profound anorexia...

3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity.

Wedge, S. R., Porteous, J. K., Newlands, E. S.

O6-benzylguanine (O6-BG) and 3-aminobenzamide (3-AB) inhibit the DNA repair proteins O6-alkylguanine-DNA alkyltransferase (AGT) and poly(ADP-ribose) polymerase (PARP) respectively. The effect of...

High-dose therapy including carboplatin adjusted for renal function in patients with relapsed or refractory germ cell tumour: outcome and prognostic factors.

Lyttelton, M. P., Newlands, E. S., Giles, C., Bower, M., Guimaraes, A., O'Reilly, S., ...

Thirty-one consecutive patients with relapsed or refractory GCT received an HDT schedule including carboplatin, the dose of which was adjusted to measured glomerular filtration rate. There was one...

A negative phase II trial methylene dimethane sulphonate in advanced ovarian cancer (Cancer Research Campaign Phase I/II Trials Committee).

Smith, D. B., Lind, M. J., Kaye, S. B., Newlands, E. S., Blackledge, G. R., Gibson, A.

Methylene dimethane sulphonate (MDMS), the first member of the homologous series of dimethane sulphonic acid esters, was administered to 19 patients with advanced epithelial ovarian cancer. All...

Phase I-II study of carboplatin vincristine methotrexate and bleomycin (COMB) in carcinoma of the cervix.

Rustin, G. J., Newlands, E. S.

Platinum based combination chemotherapy has been associated with a high response rate in patients with cervical carcinoma. To determine whether the toxicity could be reduced but the efficacy...

Bone disease in testicular and extragonadal germ cell tumours.

Hitchins, R. N., Philip, P. A., Wignall, B., Newlands, E. S., Begent, R. H., Rustin, G. J., ...

Of 297 patients with metastatic testicular and extragonadal germ cell tumours (GCT), bone involvement was detected clinically in 3% (7/251) of those at first presentation and in 9% (4/46) of relapsed...

The effect of intensity of administered treatment on the outcome of germ cell tumours treated with POMB/ACE chemotherapy.

Crawford, S. M., Newlands, E. S., Begent, R. H., Rustin, G. J., Bagshawe, K. D.

In order to assess the importance of the intensity of administration of chemotherapy in the management of advanced germ cell tumours we have calculated indices of chemotherapy. These have been used...

Long-term outcome in patients with germ cell tumours treated with POMB/ACE chemotherapy: comparison of commonly used classification systems of good and poor prognosis.

Hitchins, R. N., Newlands, E. S., Smith, D. B., Begent, R. H., Rustin, G. J., Bagshawe, K. D.

We analysed outcome in 206 consecutive male patients treated for metastatic non-seminomatous germ cell tumour (NSGCT) of testicular or extragonadal origin treated with the POMB/ACE (cisplatin,...

High-dose chemotherapy and peripheral blood stem cell support in refractory gestational trophoblastic neoplasia

El-Helw, L M, Seckl, M J, Haynes, R, Evans, L S, Lorigan, P C, Long, J, ...

We present retrospectively our experience in the use of high-dose chemotherapy and haematopoietic stem cell support (HSCS) for refractory gestational trophoblastic neoplasia (GTN) in the largest...

Loss of chromosome 10 is an independent prognostic factor in high-grade gliomas

Balesaria, S, Brock, C, Bower, M, Clark, J, Nicholson, S K, Lewis, P, ...

Loss of heterozygosity (LOH) for chromosome 10 is the most frequent genetic abnormality observed in high-grade gliomas. We have used fluorescent microsatellite markers to examine a series of 83...

Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography:a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas

Brock, C S, Young, H, O'Reilly, S M, Matthews, J, Osman, S, Evans, H, ...

Quantitation of metabolic changes in tumours may provide an objective measure of clinical and subclinical response to anticancer therapy. This pilot study assesses the value of quantitation of...

The effect of early pregnancy following chemotherapy on disease relapse and foetal outcome in women treated for gestational trophoblastic tumours

Blagden, S P, Foskett, M A, Fisher, R A, Short, D, Fuller, S, Newlands, E S, ...

Little literature exists on the safety of early pregnancy following chemotherapy. Here we assess the rate of relapse and foetal outcome in women who have completed single and multi-agent chemotherapy...